DOP2011000127A - Derivados de pirrolidina para usar como antagonistas del receptor de progesterona - Google Patents
Derivados de pirrolidina para usar como antagonistas del receptor de progesteronaInfo
- Publication number
- DOP2011000127A DOP2011000127A DO2011000127A DO2011000127A DOP2011000127A DO P2011000127 A DOP2011000127 A DO P2011000127A DO 2011000127 A DO2011000127 A DO 2011000127A DO 2011000127 A DO2011000127 A DO 2011000127A DO P2011000127 A DOP2011000127 A DO P2011000127A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compounds
- derivatives
- formula
- preparation
- pelvic pain
- Prior art date
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical class C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229960003387 progesterone Drugs 0.000 title 1
- 239000000186 progesterone Substances 0.000 title 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 2
- 208000000450 Pelvic Pain Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000005641 Adenomyosis Diseases 0.000 abstract 1
- 208000004483 Dyspareunia Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000009274 endometriosis of uterus Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000007106 menorrhagia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000030761 polycystic kidney disease Diseases 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 150000003235 pyrrolidines Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11286908P | 2008-11-10 | 2008-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2011000127A true DOP2011000127A (es) | 2011-07-15 |
Family
ID=41503565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2011000127A DOP2011000127A (es) | 2008-11-10 | 2011-05-06 | Derivados de pirrolidina para usar como antagonistas del receptor de progesterona |
Country Status (31)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR074776A1 (es) * | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
| TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑 |
| JPWO2013176220A1 (ja) * | 2012-05-25 | 2016-01-14 | 国立大学法人京都大学 | 概日リズム調整 |
| CN110041269A (zh) * | 2019-05-16 | 2019-07-23 | 海门瑞一医药科技有限公司 | 一种2-氯-5-羟基嘧啶的制备方法 |
| WO2022272060A1 (en) | 2021-06-24 | 2022-12-29 | Reservoir Neuroscience, Inc. | Ep2 antagonist compounds |
| JP2024524981A (ja) * | 2021-06-24 | 2024-07-09 | レザボア ニューロサイエンス，インコーポレイテッド | Ｅｐ２アンタゴニスト化合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5319099A (en) * | 1991-01-21 | 1994-06-07 | Shionogi Seiyaku Kabushiki Kaisha | 3-benzylidene-1-carbamoyl-2-pyrrolidone compounds useful as antiinflammatory agents |
| ES2337887T3 (es) * | 2001-12-20 | 2010-04-30 | Merck Serono Sa | Derivados de pirrolidina en calidad de moduladores de prostaglandina. |
| WO2007005176A1 (en) * | 2005-06-29 | 2007-01-11 | Allergan, Inc. | Pyrrolidinones for the treatment of glaucoma and ocular hypertension |
| US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| US7550448B2 (en) * | 2006-05-24 | 2009-06-23 | Allergan, Inc. | Therapeutic compounds |
| DE102006039912A1 (de) * | 2006-08-25 | 2008-03-20 | Bayer Healthcare Ag | Substituierte Spirotetronsäuren und ihre Verwendung |
| MX2009011998A (es) * | 2007-05-10 | 2009-11-19 | Pfizer Ltd | Derivados de azetidina y su uso como antagonistas de prostaglandina e2. |
-
2009
- 2009-10-30 MX MX2011004903A patent/MX2011004903A/es active IP Right Grant
- 2009-10-30 GE GEAP200912219A patent/GEP20125607B/en unknown
- 2009-10-30 KR KR1020117013231A patent/KR20110083733A/ko not_active Abandoned
- 2009-10-30 WO PCT/IB2009/054824 patent/WO2010052625A1/en not_active Ceased
- 2009-10-30 JP JP2011535189A patent/JP2012508225A/ja not_active Ceased
- 2009-10-30 BR BRPI0920924A patent/BRPI0920924A2/pt not_active IP Right Cessation
- 2009-10-30 CN CN2009801446055A patent/CN102209710A/zh active Pending
- 2009-10-30 EP EP09756838A patent/EP2364296A1/en not_active Withdrawn
- 2009-10-30 CA CA2741589A patent/CA2741589A1/en not_active Abandoned
- 2009-10-30 PE PE2011001004A patent/PE20110663A1/es not_active Application Discontinuation
- 2009-10-30 AP AP2011005728A patent/AP2011005728A0/xx unknown
- 2009-10-30 NZ NZ592311A patent/NZ592311A/xx not_active IP Right Cessation
- 2009-10-30 AU AU2009312427A patent/AU2009312427B2/en not_active Ceased
- 2009-10-30 EA EA201100549A patent/EA201100549A1/ru unknown
- 2009-11-06 US US12/613,771 patent/US8278343B2/en not_active Expired - Fee Related
- 2009-11-09 PA PA20098848001A patent/PA8848001A1/es unknown
- 2009-11-09 TW TW098137955A patent/TW201022234A/zh unknown
- 2009-11-09 UY UY0001032228A patent/UY32228A/es not_active Application Discontinuation
- 2009-11-10 AR ARP090104350A patent/AR074314A1/es not_active Application Discontinuation
-
2011
- 2011-04-25 CU CU20110093A patent/CU20110093A7/es unknown
- 2011-04-26 CR CR20110217A patent/CR20110217A/es unknown
- 2011-04-26 IL IL212490A patent/IL212490A0/en unknown
- 2011-04-29 TN TN2011000211A patent/TN2011000211A1/fr unknown
- 2011-05-05 EC EC2011011032A patent/ECSP11011032A/es unknown
- 2011-05-06 SV SV2011003896A patent/SV2011003896A/es unknown
- 2011-05-06 DO DO2011000127A patent/DOP2011000127A/es unknown
- 2011-05-09 NI NI201100092A patent/NI201100092A/es unknown
- 2011-05-09 CL CL2011001034A patent/CL2011001034A1/es unknown
- 2011-05-10 MA MA33829A patent/MA32782B1/fr unknown
- 2011-05-11 CO CO11058068A patent/CO6382112A2/es not_active Application Discontinuation
- 2011-06-09 ZA ZA2011/04310A patent/ZA201104310B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102209710A (zh) | 2011-10-05 |
| SV2011003896A (es) | 2011-07-05 |
| BRPI0920924A2 (pt) | 2016-10-04 |
| ECSP11011032A (es) | 2011-06-30 |
| CO6382112A2 (es) | 2012-02-15 |
| EP2364296A1 (en) | 2011-09-14 |
| ZA201104310B (en) | 2012-02-29 |
| EA201100549A1 (ru) | 2011-12-30 |
| CA2741589A1 (en) | 2010-05-14 |
| CU20110093A7 (es) | 2012-01-31 |
| IL212490A0 (en) | 2011-06-30 |
| NI201100092A (es) | 2011-10-31 |
| PE20110663A1 (es) | 2011-09-23 |
| AU2009312427A1 (en) | 2010-05-14 |
| AU2009312427B2 (en) | 2011-10-20 |
| WO2010052625A1 (en) | 2010-05-14 |
| MX2011004903A (es) | 2011-05-30 |
| UY32228A (es) | 2010-06-30 |
| US8278343B2 (en) | 2012-10-02 |
| AR074314A1 (es) | 2011-01-05 |
| TN2011000211A1 (fr) | 2012-12-17 |
| US20100120793A1 (en) | 2010-05-13 |
| CL2011001034A1 (es) | 2011-11-11 |
| JP2012508225A (ja) | 2012-04-05 |
| GEP20125607B (en) | 2012-08-10 |
| TW201022234A (en) | 2010-06-16 |
| AP2011005728A0 (en) | 2011-06-30 |
| KR20110083733A (ko) | 2011-07-20 |
| MA32782B1 (fr) | 2011-11-01 |
| CR20110217A (es) | 2011-05-12 |
| PA8848001A1 (es) | 2010-06-28 |
| NZ592311A (en) | 2012-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6382112A2 (es) | Pirrolidinas | |
| MX390698B (es) | Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos. | |
| CY1119661T1 (el) | 17-υδροξυ-17-πενταφθοροαιθυλο-οιστρα-4,9(10)-διεν-11-αρυλο-παραγωγα, μεθοδοι για την παραγωγη αυτων και χρηση αυτων για την αγωγη παθησεων | |
| SI3044206T1 (en) | (3z,5s)-5-(hydroxymethyl)-1-((2 -methyl-1,1 -biphenyl-4-yl)carbonyl)pyrrolidin-3-one o-methyloxime as oxytocin / vasopressin v1a receptors antagonists for the treatment of preterm labor | |
| UA90763C2 (ru) | Производные пиразола, способ их получения, фармацевтический состав на их основе и их применение | |
| AR049706A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| CL2009000368A1 (es) | 3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3. | |
| UY29058A1 (es) | Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato | |
| NI201200107A (es) | Moduladores alostéricos positivos de receptores m1 de la quinolina amida | |
| AR068509A1 (es) | Antagosnistas del receptor de bradiquinina b1 | |
| DOP2009000256A (es) | Derivados de azetidina y su uso como antagonistas de prostaglandina e2 | |
| UY30399A1 (es) | Uso de antagonistas de cgrp (a), sus enantinmeros, diasternmeros, mezclas y sales farmaccuticamente aceptables para preparar medicamentos, y composiciones que los contienen" | |
| ECSP10010606A (es) | Derivados de quinuclidina como antagonistas de receptores muscarinicos m3 | |
| AR062114A1 (es) | Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos. | |
| ECSP078043A (es) | Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona | |
| CO6690116A1 (es) | Nueva asociación entre la 4-[3-(cis-hexahidrociclopenta[c]pirrol -2(1h)-il]propoxi]benzamida y un antagonista de los receptores nmda y las composiciones famacéuticas que las contienen | |
| ATE525360T1 (de) | Neuartige imidazolinylmethyl-aryl-sulfonamide | |
| ECSP11010780A (es) | Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico a | |
| CR9598A (es) | Moduladores no esteroides de receptor de progesterona | |
| PH12015502326A1 (en) | Progesterone receptor antagonist dosage form | |
| UY29625A1 (es) | Uso de moduladores no esteroides de receptores de progesterona | |
| UY30805A1 (es) | Moduladores no esteroides de receptores de progesterona | |
| PA8777301A1 (es) | Antagonista del receptor de progesterona para usar en brca, solo o en combinación con un antiestrógeno | |
| CL2017002969A1 (es) | Derivados de etinilo | |
| ATE531697T1 (de) | Neuartige imidazolinylmethyl-aryl-sulfonamide |